Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EyePoint, Inc.EYPT · Entity 5702 | Director | July 12, 2024 | July 16, 2024 |
| IVERIC bio, Inc.ISEE · Entity 111416 | Director · Executive Chairman | December 18, 2020 | December 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EyePoint, Inc.
Report date July 12, 2024 · Filed July 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,850 |
Ending reported balance
After 2024-07-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-07-12 · Exercise / conversion · Acquired 3,250 · Balance 6,950 Row 2 · 2024-07-12 · Exercise / conversion · Acquired 6,525 · Balance 13,475 Row 3 · 2024-07-12 · Sale · Disposed 11,625 · Balance 1,850 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2033-06-19 | Direct | 3,250 |
Reported balance
After 2024-07-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-07-12 · Exercise / conversion · Disposed 3,250 · Balance 3,250 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.26 · Expires 2033-06-19 | Direct | 6,525 |
Reported balance
After 2024-07-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-07-12 · Exercise / conversion · Disposed 6,525 · Balance 6,525 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
IVERIC bio, Inc.
Report date December 18, 2020 · Filed December 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2030-12-17 | Direct | 205,150 |
Reported balance
After 2020-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-18 · Grant · Acquired 205,150 · Balance 205,150 F1: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 102,630 |
Reported balance
After 2020-12-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-18 · Grant · Acquired 102,630 · Balance 102,630 F2: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant.
F2: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
F3: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2019 Filed Jan 4, 2019 18:26 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,637 | $1.24 | $4,509.88 |
DisclosureSEC source: 0001104659-19-000888 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,773 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 2, 2019. F3 · price: These shares were disposed of in multiple transactions on January 3, 2019 at actual sales prices ranging from $1.23 to $1.25 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:26 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-000888 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,750 shares Expires 2025-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 2, 2015, the reporting person was granted an award of 23,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:26 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 5,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-000888 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 17:15 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantRestricted Stock Units · Derivative | 68,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073133 · a4.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,800 Underlying: Common Stock · 68,800 shares Expires 2028-12-11 F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 17:15 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001104659-18-073133 · a4.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2028-12-11 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant. Read SEC document |
| January 05, 2018 Filed Jan 5, 2018 17:21 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,798 | $3.17 | $12,039.66 |
DisclosureSEC source: 0001104659-18-001012 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,660 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2018. F3 · price: These shares were disposed of in multiple transactions on January 5, 2018 at actual sales prices ranging from $3.16 to $3.19 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:21 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-001012 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 4, 2016, the reporting person was granted an award of 25,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:21 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-001012 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,516 | $3.24 | $11,391.84 |
DisclosureSEC source: 0001104659-18-000812 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,208 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 2, 2018. F3 · price: These shares were disposed of in multiple transactions on January 3, 2018 at actual sales prices ranging from $3.24 to $3.25 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:00 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 16,520 | $3.19 | $52,698.80 |
DisclosureSEC source: 0001104659-18-000565 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,974 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on December 29, 2017. F3 · price: These shares were disposed of in multiple transactions on January 2, 2018 at actual sales prices ranging from $3.10 to $3.25 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-000812 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2025-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 2, 2015, the reporting person was granted an award of 23,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 5,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-000812 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 17:00 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 30,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-000565 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,480 shares Expires 2027-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 17, 2017, the reporting person was granted an award of 60,960 restricted stock units, which vested with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 17:00 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 30,480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-000565 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 17:08 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001104659-17-074631 · a4.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:34 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 17,678 | $2.58 | $45,609.24 |
DisclosureSEC source: 0001104659-17-043659 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,014 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on June 30, 2017. F3 · price: These shares were disposed of in multiple transactions on July 5, 2017 at actual sales prices ranging from $2.55 to $2.64 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:34 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 30,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-043659 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,480 Underlying: Common Stock · 30,480 shares Expires 2027-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 17, 2017, the reporting person was granted an award of 60,960 restricted stock units, which vests with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:34 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 30,480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-043659 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001104659-17-005852 · a4.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2027-01-29 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:36 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantRestricted Stock Units · Derivative | 60,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-003127 · a4.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,960 Underlying: Common Stock · 60,960 shares Expires 2027-01-16 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: Subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan and the reporting person's employment agreement, the award of restricted stock units will vest with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,785 | $4.96 | $18,773.60 |
DisclosureSEC source: 0001104659-17-001233 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,212 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2017. F3 · price: These shares were disposed of in multiple transactions on January 5, 2017 at actual sales prices ranging from $4.90 to $5.04 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-001233 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 4, 2016, the reporting person was granted an award of 25,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001233 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 17:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,484 | $4.90 | $17,071.60 |
DisclosureSEC source: 0001104659-17-000647 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,747 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 2, 2017. F3 · price: These shares were disposed of in multiple transactions on January 3, 2017 at actual sales prices ranging from $4.85 to $4.98 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000647 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 5,750 shares Expires 2025-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 2, 2015, the reporting person was granted an award of 23,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 5,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-000647 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 21:35 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionStock Options (Right to Buy) · Derivative | 22,060 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-16-154726 · a4.xml · derivative · entry 5 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,636 Underlying: Common Stock · 22,060 shares Expires 2023-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on April 26, 2013 and vests as to 1/48 of the shares underlying such option each month until April 2017. F6 · balance_after: Represents the aggregate number of options remaining from each of two awards that were granted to the Reporting Person on April 26, 2013, each of which has an expiration date of April 25, 2023 and an exercise price of $10.03 per option. These two awards were previously reported separately by the Reporting Person. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 21:35 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,820 | $36.86 | $140,805.20 |
DisclosureSEC source: 0001104659-16-154726 · a4.xml · nonDerivative · entry 4 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,481 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. F4 · price: These shares were disposed of in multiple transactions on November 1, 2016 at actual sales prices ranging from $36.41 to $37.305 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 21:35 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 7,710 | $35.93 | $277,020.30 |
DisclosureSEC source: 0001104659-16-154726 · a4.xml · nonDerivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,301 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. F3 · price: These shares were disposed of in multiple transactions on November 1, 2016 at actual sales prices ranging from $35.41 to $36.40 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 21:35 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 10,530 | $34.93 | $367,812.90 |
DisclosureSEC source: 0001104659-16-154726 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,011 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. F2 · price: These shares were disposed of in multiple transactions on November 1, 2016 at actual sales prices ranging from $34.38 to $35.32 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 21:35 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 22,060 | $10.03 | $221,261.80 |
DisclosureSEC source: 0001104659-16-154726 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:16 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionStock Options (Right to Buy) · Derivative | 16,210 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-16-148935 · a4.xml · derivative · entry 5 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 Underlying: Common Stock · 16,210 shares Expires 2023-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on April 26, 2013 and vests as to 1/48 of the shares underlying such option each month until April 2017. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:16 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 1,600 | $45.97 | $73,552.00 |
DisclosureSEC source: 0001104659-16-148935 · a4.xml · nonDerivative · entry 4 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,481 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. F4 · price: These shares were disposed of in multiple transactions on October 3, 2016 at actual sales prices ranging from $45.355 to $46.22 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:16 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 6,632 | $44.77 | $296,914.64 |
DisclosureSEC source: 0001104659-16-148935 · a4.xml · nonDerivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. F3 · price: These shares were disposed of in multiple transactions on October 3, 2016 at actual sales prices ranging from $44.39 to $45.28 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:16 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 13,828 | $44.00 | $608,432.00 |
DisclosureSEC source: 0001104659-16-148935 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,713 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. F2 · price: These shares were disposed of in multiple transactions on October 3, 2016 at actual sales prices ranging from $43.39 to $44.38 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:16 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 16,210 | $10.03 | $162,586.30 |
DisclosureSEC source: 0001104659-16-148935 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 17:15 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 24,060 | $52.58 | $1,265,074.80 |
DisclosureSEC source: 0001104659-16-143256 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,331 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2015. F2 · price: These shares were disposed of in multiple transactions on September 1, 2016 at actual sales prices ranging from $52.385 to $53.00 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.